Gastric cancer
Conditions
Interventions
Observation group (robot group):None
Control group (laparoscopic group):None
Sponsors
The First Affiliated Hospital of the Army Medical University of the People's Liberation Army of China
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1.Age >18 years old, <75 years old; 2.Pathologically confirmed as adenocarcinoma of the esophagogastric junction (Siewert II and III types), the pathological types include papillary adenocarcinoma, tubular adenocarcinoma, mucinous adenocarcinoma, and signet ring cell carcinoma; 3.Before neoadjuvant therapy, the clinical stage was confirmed as cII-cIII (cT2N+M0, cT3-4aN0/+M0) by gastroscopy + endoscopic ultrasound, enhanced CT, and PET-CT (optional), based on the AJCC 8th edition TNM staging system. 4.Preoperative examination revealed no distant metastasis, and the tumor did not directly invade the pancreas, spleen or other adjacent organs. 5.The number of cycles for neoadjuvant chemotherapy combined with immunotherapy is not limited. The treatment plan includes: SOX + ICIs or Xelox++ICIs; 6.After neoadjuvant therapy, after discussion by the MDT, radical surgery (R0 resection is expected) was deemed feasible, and robotic or laparoscopic radical resection surgery was accepted. 7.Preoperative ECOG physical status score: 0-1 points; 8.Preoperative ASA score: I-III level; 9.The clinical data are complete (including records of neoadjuvant therapy, surgical records, pathological reports, and follow-up data);
Exclusion criteria
Exclusion criteria: 1.It was confirmed during or after the operation to be in stage M1 (distant metastasis) or stage T4b. 2.There is a history of previous abdominal surgery (excluding laparoscopic cholecystectomy and appendectomy). 3.Having a history of other malignant tumors within the past 5 years; 4.Combined with severe dysfunction of the heart, lungs, liver and kidneys, unable to tolerate surgery; 5.Complications of gastric cancer (bleeding, perforation, obstruction) requiring emergency surgery; 6.The clinical data is incomplete (key data is missing).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Overall survival; | — |
Countries
China
Contacts
Public ContactShi Yan
The First Affiliated Hospital of the Army Medical University of the People's Liberation Army of China
Outcome results
None listed